Resultados de procura - Edward R. Scheffer Cliff

  • Mostrando 1 - 10 Resultados de 10
Limitar resultados
  1. 1
    Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma

    Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma por Edward R. Scheffer Cliff, Gemma Reynolds, Rakesh Popat, Benjamin W. Teh, Aaron S. Kesselheim, Ghulam Rehman Mohyuddin

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  2. 2
    High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions

    High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions por Edward R. Scheffer Cliff, Amar H. Kelkar, David A. Russler‐Germain, Frazer A. Tessema, Adam Raymakers, William B. Feldman, Aaron S. Kesselheim

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis

    Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis por Gemma Reynolds, Marsali Maclean, Edward R. Scheffer Cliff, Benjamin W. Teh, Karin Thursky, Monica A. Slavin, Mary Ann Anderson, Eliza A. Hawkes

    Publicado 2024
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  4. 4
    Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis

    Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis por Gemma Reynolds, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin, Rakesh Popat, Shonali Midha, Melissa Ng, Simon J. Harrison, Aaron S. Kesselheim, Benjamin W. Teh

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  5. 5
    The lucent yet opaque challenge of regulating artificial intelligence in radiology

    The lucent yet opaque challenge of regulating artificial intelligence in radiology por James Hillis, Jacob J. Visser, Edward R. Scheffer Cliff, Kelly van der Geest – Aspers, Bernardo C. Bizzo, Keith J. Dreyer, Jeremias Adams‐Prassl, Katherine P. Andriole

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

    Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma por Tobias Tix, Mohammad Alhomoud, Roni Shouval, Gloria Iacoboni, Edward R. Scheffer Cliff, Doris K. Hansen, Saad Z. Usmani, Gilles Salles, Miguel‐Angel Perales, David M. Cordas dos Santos, Kai Rejeski

    Publicado 2025
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  7. 7
    Dietary interventions in cancer: a systematic review of all randomized controlled trials

    Dietary interventions in cancer: a systematic review of all randomized controlled trials por Nosakhare Paul Ilerhunmwuwa, Abul Hasan Shadali Abdul Khader, Calvin Smith, Edward R. Scheffer Cliff, Christopher M. Booth, Evevanne Hottel, Muhammad Aziz, Wade Lee‐Smith, Aaron M. Goodman, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  8. 8
    A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

    A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy por David M. Cordas dos Santos, Tobias Tix, Roni Shouval, Anat Gafter‐Gvili, Jean-Baptiste Alberge, Edward R. Scheffer Cliff, Sebastian Theurich, Michael von Bergwelt‐Baildon, Irene M. Ghobrial, Kai Rejeski, Miguel‐Angel Perales, Kai Rejeski

    Publicado 2024
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  9. 9
    Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

    Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition por Thomas E. Lew, Victor S. Lin, Edward R. Scheffer Cliff, Piers Blombery, Ella R. Thompson, Sasanka M. Handunnetti, David Westerman, Bryone J. Kuss, Constantine S. Tam, David C.S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson

    Publicado 2021
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

    Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma por Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Anikó Szabó, Carolina Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D’Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin Kaiser, Melissa Ng, Simon J. Harrison, Edward R. Scheffer Cliff, Meera Mohan

    Publicado 2024
    Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: